Mechanism of p27 Unfolding for CDK2 Reactivation

Soumya Lipsa Rath1, Sanjib Senapati1

  • 1Computational Biophysics Group, Bhupat and Jyoti Mehta School of Biosciences and Department of Biotechnology, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India.

Scientific Reports
|May 24, 2016
PubMed

Insights

Phosphorylation of p27 protein triggers CDK2 reactivation by disrupting its binding and ejecting a key helix. This two-step process restores CDK2/CyclinA activity, crucial for cell-cycle regulation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Structural Biology

Background:

  • Cyclin-dependent kinase 2 (CDK2) activity is regulated by cyclins and inhibitors like p27.
  • While CDK2 inhibition by p27 is understood, the reactivation mechanism remains unclear.

Purpose of the Study:

  • To elucidate the molecular mechanism of CDK2 reactivation from p27 inhibition.
  • To investigate the role of p27 phosphorylation in CDK2/CyclinA complex dynamics.

Main Methods:

  • Classical and accelerated molecular dynamics simulations.
  • Analysis of unphosphorylated- and phosphorylated-p27 bound CDK2/CyclinA complexes.
  • Comparison with NMR chemical shift data and kinetic experiments.

Main Results:

  • Phosphorylation of p27 at Y88 disrupts the p27/CDK2 interaction and ejects the p27 310 helix.
  • CDK2 reactivation follows a two-step unfolding mechanism, with helix ejection as the rate-limiting step.
  • Reactivated CDK2/CyclinA regains essential contacts and ATP binding for kinase activity.

Conclusions:

  • The study reveals a detailed molecular mechanism for CDK2 reactivation.
  • Phosphorylated p27 acts as a trigger for releasing CDK2 inhibition.
  • Findings provide insights into cell-cycle control and potential therapeutic targets.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K